Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
monoclonal antibodies
Biotech
Regeneron antibodies post ph. 3 wins against cat, pollen allergy
Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen allergies in a pair of phase 3 studies.
James Waldron
Sep 8, 2025 9:54am
Junshi sees ph. 3 psoriasis win for IL-17 drug, preps China push
Sep 8, 2025 4:54am
Allogene reports patient death tied to mAb in CAR-T pivotal trial
Aug 1, 2025 8:30am
Roche's COPD drug flunks ph. 3, denting hopes of 2025 approval
Jul 21, 2025 4:38am
Hummingbird uses VISTA buzz to secure $290M pact for tumor drug
Jun 26, 2025 4:53am
Prothena lays off 63% in fallout from phase 3 amyloidosis fail
Jun 20, 2025 2:23am